Compare
Nektar Therapeutics vs Integrated Biopharma Inc vs Aytu Biopharma, Inc vs Ocular Therapeutix, Inc
| Latest fiscal year | Nektar Therapeutics NKTR | Integrated Biopharma Inc INBP | Aytu Biopharma, Inc AYTU | Ocular Therapeutix, Inc OCUL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-06-30 | 2026-06-30 | 2025-12-31 |
| Revenue | $55.23M | $54.35M | $57.57M | $51.95M |
| Revenue growth (YoY) | -43.9% | +8.0% | -13.3% | -18.5% |
| Gross margin | n/a | 10.2% | 64.0% | 87.3% (computed) |
| Operating margin | -253.7% | 3.7% | -14.4% | -519.8% |
| Net margin | -297.1% | 1.5% | -24.8% | -511.9% |
| Net income | -$164.08M | $808.0K | -$14.25M | -$265.94M |
| EPS (Diluted) | -$9.73 | $0.03 | n/a | -$1.42 |
| Operating cash flow | -$208.51M | $2.06M | $3.28M | -$204.88M |
| Free cash flow | -$208.68M | $1.87M | $3.25M | -$216.89M |
| Cash & equivalents | $15.12M | $3.62M | $26.31M | $737.06M |
| Total assets | $280.41M | $24.90M | $105.01M | $808.06M |
| Total liabilities | $190.57M | $4.58M | n/a | $153.75M |
| Shareholders' equity | $89.83M | $20.32M | $35.27M | $654.31M |
| Return on year-end equity | -182.6% | 4.0% | -40.4% | -40.6% |
| Shares outstanding | 20.38M | 31.06M | 10.73M | 215.93M |
Revenue, most recent five fiscal years
| Fiscal year | Nektar Therapeutics | Integrated Biopharma Inc | Aytu Biopharma, Inc | Ocular Therapeutix, Inc |
|---|---|---|---|---|
| Latest | $55.23M Ended 2025-12-31 | $54.35M Ended 2025-06-30 | $57.57M Ended 2026-06-30 | $51.95M Ended 2025-12-31 |
| 1 year earlier | $98.43M Ended 2024-12-31 | $50.32M Ended 2024-06-30 | $66.38M Ended 2025-06-30 | $63.72M Ended 2024-12-31 |
| 2 years earlier | $90.12M Ended 2023-12-31 | $50.67M Ended 2023-06-30 | $65.18M Ended 2024-06-30 | $58.44M Ended 2023-12-31 |
| 3 years earlier | $92.06M Ended 2022-12-31 | $56.25M Ended 2022-06-30 | $107.40M Ended 2023-06-30 | $51.49M Ended 2022-12-31 |
| 4 years earlier | $101.91M Ended 2021-12-31 | $63.56M Ended 2021-06-30 | $96.67M Ended 2022-06-30 | $43.52M Ended 2021-12-31 |